AI
Tuesday, February 09, 2021 6:06:38 AM
Relief Therapeutics Valuation Report
“What a Relief!”
Prepared to be transformational
Key catalysts include:
1. Topline results RLF-100 “COVID-AIV” trial in COVID-19 ARDS (late Jan/early Feb 2021)
2. Potential US Emergency Use Authorization for RLF-100 COVID-19 ARDS (Q1 2021)
3. Start RLF-100 “AVICOVID-2” trial in COVID-19 NALI (early 2021)
vL Relief Therapeutics Valuation Report
https://www.valuationlab.com/research/
just another investor!
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
